Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With 100% Alcon Ownership, Novartis Forms New Eye Care Unit

This article was originally published in The Gray Sheet

Executive Summary

Novartis will create a new eye care division – representing the fifth growth platform in its health care portfolio – after acquiring full ownership of ophthalmology specialist Alcon.

You may also be interested in...



Novartis Completes Deal For Nestle's Share In Alcon

For Novartis, acquiring the first 77% of Alcon might have been the easy part. Novartis said Aug. 26 that it had closed its deal to acquire 52% of Alcon from Nestle for $28.3 billion in cash, on top of the 25% it acquired from the same company in 2008

Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover

In a strong sign of Novartis' long-term commitment to ophthalmology, the firm announced Jan. 4 that it would exercise its option to purchase Nestlé's remaining 52% stake in eye-care group Alcon for $28.1 billion and separately pursue a buyout of the 23% of shares owned by independent stockholders

Novartis Sets $39 Billion Path To Purchasing Eye Care Market Leader Alcon

Diversified drug, diagnostics and ophthalmic device giant Novartis will acquire a 25% stake in eye care market leader Alcon as a first step toward potentially gaining majority ownership of the company by 2011, the firms announced April 7

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel